Quest Diagnostics (NYSE:DGX) recently announced that it has expanded its endocrine diagnostics portfolio with the recent introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder mostly found in newborns, children and women. Quest Diagnostics claims that the new CAH panels of tests, based on advanced analytical-test method, will increase patient care by fast detection and treatment of CAH in comparison with traditional tests. The new panels of tests have … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards